ThirdLaw Molecular, a Blue Bell-based Temple University spinout, was featured by The Philadelphia Business Journal for “advancing a new technology it believes can be used to design and create more effective drugs faster and cheaper than those currently available.”

Dr. Christian Schafmeister, ThirdLaw’s founder and president, is creating a “revolutionary” category of molecules via the company’s Spiroligomer technology.

“Spiroligomer molecules have complex structures that allow them to selectively target proteins that are involved in disease,” Schafmeister told The Journal. “They are synthetic in origin — making them easy to manufacture and store.”

Earlier this month, ThirdLaw launched its first library of 4.5 billion Spiroligomer macromolecules, which contain unique DNA sequences. The hope is it will be a springboard for partnerships with larger pharmaceutical companies.

ThirdLaw’s business strategy is to pursue such partnerships and develop select molecules internally as therapeutics, initially as potential cancer therapies and for anti-inflammatory drugs.

The company has secured $16 million in grants from the U.S. Department of Defense.

“When I was a child, I didn’t want to be a chemist; I wanted to be a wizard,” he said. “I still want to make magic. I want to make molecules that work like magic.”

Photo: X.com